Sugi Predict

Sugi Predict / Compounds / SCHEMBL4402310

SCHEMBL4402310

SCHEMBL4402310

COC(=O)/C(=C/c1cccc(/C=C/c2cccc(/C=C(/NC(C)=O)C(=O)OC)c2)c1)NC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ ALDH1A1 P00352 7/20 0.42
▸ MAPT P10636 2/20 0.42
▸ LMNA P02545 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ABCB1 P08183 2/20 0.40
▸ P4HB P07237 2/20 0.38
▸ APP P05067 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4402313 1.00 MEN1 (0.46) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL9135884 0.88 ALDH1A1 (0.53) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL9135881 0.88 ALDH1A1 (0.53) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL4406233 0.85 KMT2A (0.47) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL4406236 0.85 KMT2A (0.47) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL13906652 0.85 MAPT (0.46) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL27555919 0.85 CYP1A2 (0.46) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL3914295 0.85 NPSR1 (0.45) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL27533540 0.85 MAPT (0.46) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL3914299 0.85 NPSR1 (0.45) MEN1KMT2AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 — — US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 — — US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 — — US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 — — US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 MEN1 4070/4885KMT2A 2002/4885ALDH1A1 2926/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A MEN1 3751/4885KMT2A 3334/4885ALDH1A1 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.